Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00664417 | Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine | PHASE1 | COMPLETED | 375 | — | — | Apr 1, 2008 | Aug 1, 2010 | Apr 17, 2012 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | ACTIVE_COMPARATOR | - |
| 8 | ACTIVE_COMPARATOR | - |
| 9 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Monovalent subvirion H5N1 influenza vaccine | BIOLOGICAL | 0.5 mL, IM, 2 injections, Formulation 1 |
| Physiological saline | BIOLOGICAL | 0.5 mL, IM, 2 injections |
Inclusion Criteria : * Healthy adult aged 18 to 40 years on the day of inclusion. * Provides signed informed consent prior to study procedures. * Able to attend all scheduled visits and comply with all trial procedures. * For a woman of child-bearing potential, avoid becoming pregnant (use of an ef...